Patient: Page 28
-
PharmaVoice Team/PharmaVoice
Salesforce Effectiveness: Is the Decile Model Becoming Outmoded?
By Robin Robinson For years pharmaceutical sales teams have targeted physicians based solely on their prescribing volume. Technology advances, process enhancements, and new messaging formats are offering new and improved ways of accessing physicians. Can salesforce optimization technology become ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Alternative Media
By Robin Robinson Other industries are venturing into the uncharted waters of emerging and alternative media, but for the most part pharma has decided for now to stay at the shallow end of the pool. There are a few adventurous leaders using more avant-garde methods, such as digital billboards, Po...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Cancer: Harnessing the Power of the Immune System
These pictures illustrate how Micromet’s BiTE molecule links a T cell with a cancer cell (left), triggering the release of toxic particles by the T cell (middle), and the cancer cell being destroyed (right). This is one approach for employing the body’s immune system to address cancer. Cancer tre...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Solutions Adoption is a Marathon not a Sprint
VIEW on E-Solutions October 2006 E-Solutions Adoption is a Marathon not a Sprint By Daniel Limbach Any mention of e-solutions involves a wide range of technologies. For the purposes of continuity and this publication, we view e-solutions as any electronically based, interactive technol...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Midsize Pharma: Moving & Shaking the Industry
By Taren Grom, Editor Unlike their large pharmaceutical counterparts, midsize pharmaceutical companies are usually not constrained by huge overheads or layers of bureaucracy. What these companies do have is a more narrow business focus, which allows them to concentrate on specific areas of drug...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
A 360-Degree Approach to Marketing With the Patient at the Center
By Taren Grom A 360-Degree Approach to Marketing With the Patient at the Center As budgets start to shift away from mass-media DTC efforts and slick and glitzy advertising, marketers are going old school, in a sense. There is more focus on the healthcare providers, not just as prescri...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Name That Brand
Choosing a brand name is the most defining moment in a pharmaceutical product’s life. Name That Brand September 2006 Apharmaceutical product’s brand name is more than a series of letters that identify a chemical compound or biological agent used to treat a specific condition. The brand name evoke...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Risk Takers
The entrepreneurial spirit runs deep in these industry vanguards as they carve out new market niches and provide solutions and technologies to improve the healthcare process. Dr. Robert Friedman Pioneering Patient-Centric Telemedicine Patients need to understand why they are prescribed their medi...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Sales Training Has Never Been More Important
Sales Training has Never Been More Important The Forum By Daniel Limbach Knowledge, relationship building, and technology are some of the key factors that can make a good rep a great rep. More important than ever. Knowledge, relatio...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Star Quality
PharmaVOICE is once again honored to pay tribute in the following pages to the Healthcare Businesswomen’s Association (HBA) Rising Stars. The Class of 2006 represents a wide range of disciplines, company types, and levels of accomplishment. These women have one thing in common: they have been ide...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Building on Momentum
Building on Momentum The Forum VIEW on Biotech April 2006 In 2005, biotech companies maintained the momentum that began in 2004, fueled by revenue from marketed biotech drugs ? more than $33 billion in sales. In 2005, Amgen retained its spot as the top bio force with four of the top-...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Drugs in the Real World
By Denise Myshko A greater regulatory focus on safety means companies are under pressure to provide more information about a prescription drug, as well as about the characteristics of patients, once a product becomes available to the larger marketplace. companies are being asked to provide inform...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Medicine Cabinet
Compounds have a one in nine chance of making it through development, according to statistics, but even after reaching the market, each compound faces a whole new set of hurdles: physician adoption, reimbursement, and exposure to supply chain vulnerabilities. December 2005 On the Market Advertisi...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Marketing's New Frontiers
Primed for a Marketing Revolution According to industry experts, there is going to be a shift in marketing that will include: a move away from rational marketing to emotional brand marketing; initiatives that start earlier in the development cycle with end goals identified; marketing programs th...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Change Agents
The Change Agents Identified as vanguards in their respective sectors, these industry leaders are challenging the status quo to make a difference. Dr. Amrit Ray All-Around Global Medical Leadership A passionate leader devoted to bringing new medicines to patients for conditions to which cures hav...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Modern Marketing in the Making
By Elisabeth Pena Modern Marketing in the Making September 2004 VIEW on Marketing Marketing executives from pharmaceutical, biotechnology, device, and diagnostic companies, ranging in size from small specialty to midtier to large and global, share the common challenges of shorter product life ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The State of Advertising
The State of Advertising The commercialization and promotion of pharmaceutical products depends on relationships for success. The attitudes, personalities, and respect that exist throughout the pharmaceutical advertising landscape play an important role in the evolution of a brand, and are a v...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry Pharma POOL Robert Boisclair Dr. Richard Bowles Steve Chellevold Mary-Frances Faraji Brent Saunders Schering-Plough Announces Senior-Level Management Changes Schering-Plough, Kenilworth, N.J., has made senior-level management change...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Value of Phase IV
BY Elisabeth Pena The Value of Phase IV Postmarketing research can be crucial for tracking side effects and exploring new uses for an approved drug. But these trials are heavily scrutinized because some say pharma companies have conducted such studies purely for promotional purposes with little s...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Prioritizing the Pipeline: The Critical Role of Porfolio Management
Prioritizing the Pipeline The critical role of portfolio management Increased pressures on the pharmaceutical industry – shrinking pipelines, rising costs, reimbursement issues, regulatory pressures, and consumer demands – mean companies have to find ways to focus on the projects that will meet c...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
talent pool executive appointments and promotions in the healthcare industry Pharma POOL Robert Bertolini Schering-Plough Appoints Executive VP, Chief Financial Officer Schering-Plough has appointed Robert J. Bertolini as executive VP and chief financial officer. He also serves on the Schering-Pl...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Kareem Saad -- Big Blue's Genomics Ace
By Kim Ribbink Big Blue’s Genomics Ace Young and talented, Kareem Saad, IBM’s worldwide business segment executive for clinical genomics, is overseeing the company’s initiative to take clinical genomics from concept to market. With youthful enthusiasm, innate technical and scientific intelligence...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Talent Pool Executive Appointments and Promotions in the Healthcare Industry Pharma POOL Joy A. Amundson Bruce McGillivray Jim Utts Baxter Appoints and Promotes Executives Baxter International has named Joy A. Amundson corporate VP and president of its bioscience business. Baxter, Deerfield, Ill....
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Secret to Alliance Success
Pharma Forum The Secret to Alliance Success By Denise Myshko Successful partnerships involve more than just signing a contract. Bringing drugs to market and then marketing those products more than ever hinges on how well alliances are managed from a strategic, operational, and organizational stan...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Risky Business
Risky Business By Elisabeth Pena The pharmaceutical industry faces more inherent risks and higher stakes than almost any other industry because its products impact patient safety and well-being. Intensified public and media scrutiny about medication errors and drugs being pulled off the market ha...
By PharmaVoice Team • Jan. 2, 2008
Previous
